Dacarbazine

Dacarbazine
Clinical data
Pronunciation	/dəˈkɑːrbəˌziːn/
Trade names	DTIC-Dome, others
Other names	DTIC
AHFS/Drugs.com	Monograph
MedlinePlus	a682750
Routes of; administration	Intravenous
ATC code	L01AX04 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	100%
Metabolism	Extensive
Elimination half-life	5 hours
Excretion	Kidney (40% as unchanged dacarbazine)
Identifiers
	IUPAC name 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide;
CAS Number	4342-03-4 ;
PubChem CID	2942;
DrugBank	DB00851 ;
ChemSpider	10481959 ;
UNII	7GR28W0FJI;
KEGG	D00288 ; C06936;
ChEBI	CHEBI:4305 ;
ChEMBL	ChEMBL476 ;
ECHA InfoCard	100.022.179
Chemical and physical data
Formula	C6H10N6O
Molar mass	182.187 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)N=Nc1[nH]cnc1C(N)=O;
	InChI InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+ ; Key:FDKXTQMXEQVLRF-ZHACJKMWSA-N ;
	(what is this?) (verify)

Dacarbazine, also known as imidazole carboxamide and sold under the brand name DTIC-Dome, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma. For Hodgkin's lymphoma, it is often used together with vinblastine, bleomycin, and doxorubicin. It is given by injection into a vein.

Common side effects include loss of appetite, vomiting, low white blood cell count, and low platelets. Other serious side effects include liver problems and allergic reactions. It is unclear if use in pregnancy is safe for the baby. Dacarbazine is in the alkylating agent and purine analog families of medication.

Dacarbazine was approved for medical use in the United States in 1975. It is on the World Health Organization's List of Essential Medicines.